EntryPoint Capital LLC Makes New $275,000 Investment in Personalis, Inc. (NASDAQ:PSNL)

EntryPoint Capital LLC purchased a new stake in shares of Personalis, Inc. (NASDAQ:PSNL) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 47,513 shares of the company’s stock, valued at approximately $275,000.

Other institutional investors have also added to or reduced their stakes in the company. Jane Street Group LLC grew its stake in shares of Personalis by 154.3% during the 3rd quarter. Jane Street Group LLC now owns 164,281 shares of the company’s stock valued at $884,000 after purchasing an additional 99,671 shares during the period. abrdn plc bought a new position in Personalis in the 4th quarter worth $1,722,000. Walleye Capital LLC purchased a new stake in shares of Personalis during the third quarter worth about $897,000. Barclays PLC grew its holdings in Personalis by 45.4% during the 3rd quarter. Barclays PLC now owns 65,468 shares of the company’s stock valued at $352,000 after buying an additional 20,444 shares in the last quarter. Finally, State Street Corp grew its stake in Personalis by 34.5% during the third quarter. State Street Corp now owns 175,142 shares of the company’s stock valued at $942,000 after acquiring an additional 44,900 shares in the last quarter. 61.91% of the stock is currently owned by hedge funds and other institutional investors.

Personalis Trading Up 1.1 %

Shares of NASDAQ PSNL opened at $3.62 on Friday. The stock has a market capitalization of $319.51 million, a PE ratio of -2.15 and a beta of 1.73. Personalis, Inc. has a 12-month low of $1.14 and a 12-month high of $7.20. The stock’s fifty day simple moving average is $4.60 and its two-hundred day simple moving average is $4.80.

Personalis (NASDAQ:PSNL) last posted its earnings results on Thursday, February 27th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.09. The company had revenue of $16.80 million during the quarter, compared to analysts’ expectations of $15.48 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. On average, equities analysts predict that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Personalis in a research note on Friday, February 28th. Needham & Company LLC reduced their price objective on shares of Personalis from $7.25 to $7.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Craig Hallum initiated coverage on Personalis in a research note on Monday, March 17th. They issued a “buy” rating and a $8.00 target price on the stock. Finally, Lake Street Capital lifted their price target on shares of Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Personalis has a consensus rating of “Buy” and a consensus price target of $7.80.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.